DAYTON, Ohio, April 9, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. patent application No. 10/713,929, entitled “Modified Release Dosage Forms of Skeletal Muscle Relaxants.” Eurand’s patent application was filed November 14, 2003 and includes allowed claims covering Amrix(r), a product currently marketed in the U.S. by Cephalon under license from Eurand. Amrix is the only approved once-daily formulation of the skeletal muscle relaxant, cyclobenzaprine hydrochloride, for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.
